Dare Bioscience (DARE) announced a contract with the Gates Foundation under which it can receive up to approximately $300,000 to conduct a strategic landscape review of organizations with capabilities relevant to contraceptive product development. Under this contract, Dare will work to identify and assess for-profit and non-profit organizations worldwide with demonstrated capabilities in formulation development, clinical and commercial manufacturing, clinical trial design, and regulatory support for contraceptive products.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Daré Bioscience Advances Progesterone Delivery Study for Preterm Birth Prevention
- Daré Bioscience’s Ovaprene Study: A New Era in Contraceptive Innovation
- Dare Bioscience receives $4M non-dilutive grant installment
- Dare Bioscience to receive up to $499,000 to support preeclampsia research
- Daré, AMD, Twilio, UiPath, Luckin: Trending by Analysts